Compare Sana Biotechnology Inc (SANA) vs Zscaler Inc (ZS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs Zscaler Inc — how do they compare? Sana Biotechnology Inc trades at $3.17 (market cap $873.84M), while Zscaler Inc trades at $148.6 (market cap $24.23B). The key difference: Zscaler Inc is far larger — about 27.7× Sana Biotechnology Inc's market cap. Which is the better fit depends on your goals.
| SANA | ZS | |
|---|---|---|
Market Cap | $873.84M | $24.23B |
Sector | Health | Technology |
52-Week High | $5.92 | $336.27 |
52-Week Low | $2.68 | $118.05 |
Enterprise Value | $848.03M | $22.55B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Zscaler trades at $148.72, down 0.78% on the day, with strong technical momentum showing bullish moving average signals and key support at $147. The company demonstrates robust revenue growth, increasing from $1.1B in 2022 to $2.67B in 2025, while narrowing net losses from -$390M to -$41M. Recent earnings beats and accelerating Zero Trust adoption position Zscaler for continued enterprise security market share gains amid growing cybersecurity spending trends.
Zscaler presents a compelling growth story with 79% analyst buy ratings and a $192.46 price target offering 29% upside potential. However, persistent profitability challenges, rising AI infrastructure costs, and ongoing class action investigations create near-term execution risks. The stock's premium valuation at 7.5x sales requires sustained revenue acceleration to justify current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About Zscaler Inc
Zscaler is a security-as-a-service firm that offers its customers cloud-delivered solutions for protecting user devices and data. The firm leverages its position in 150 colocation data centers to deliver traditionally appliance-based security functionality, such as firewalls and sandboxes, as a completely cloud-native platform. The firm focuses on large enterprise customers and offers two primary product suites: Zscaler Internet Access, which securely connects users to externally managed application and websites (such as Salesforce and Google), and Zscaler Private Access, which securely connects users to internally managed applications. Both product suites encompass a broad gamut of capabilities situated across the traditional security stack.
Read more on ZS →
